Huntsworth plc announced that Liz McKee Anderson will join the Board of Directors as an independent non-executive director. Liz has extensive experience in the pharmaceuticals industry, notably having held a number of senior executive roles at Johnson & Johnson. Since April 2017, Liz has been a Board Director of Bavarian Nordic A/S, a biotechnology company listed on the Danish stock exchange. Liz is also an Independent Board Director of Revolution Medicines Inc. She holds a number of other positions in both commercial and non-profit spheres, including the Wistar Institute. Andy Boland will be appointed as Huntsworth's Senior Independent Director. Andy has been a director of Huntsworth plc since 11 August 2014, has previously served as the chair of the Audit Committee and remains as a member of both the Audit and Nomination Committees. All to be effective from January 1, 2018.
Huntsworth Limited is a United Kingdom-based intermediate holding company. The Company is engaged in healthcare and communication activities. The Company, through its subsidiaries, is focused on health that provides marketing and medical communications services to healthcare clients, which are primarily large and mid-size pharmaceuticals and biotechnology companies. It also provides a range of communications and advisory services, including strategic communications, public affairs, investor relations and consumer marketing. The Companyâs financial instruments comprise bank loans, bank overdrafts, loan notes, and cash and short-term deposits. The Companyâs geographical areas include the United Kingdom, Europe, the United States and the rest of the world. The Companyâs subsidiaries operate in approximately 28 in the United Kingdom and Europe.
HUNTSWORTH PLC 
